AstraZeneca is trying to blaze a new trial for immunotherapy in liver cancer with its EMERALD-1 trial, but the jury is out on its prospects. The study of PD-L1 inhibitor Imfinzi (durvalumab ...
it recently chalked up an impressive win for Imfinzi in hepatocellular carcinoma (HCC) – the most common form of liver cancer – in the EMERALD-1 study. “Our goal with the PACIFIC-2 trial was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback